CLINICAL APPLICATION & CRITERIA
Targeted Therapy in China
Targeted therapy uses drugs designed to interfere with specific molecular drivers of cancer growth — mutated proteins, overexpressed receptors, or activated signaling pathways — rather than attacking all rapidly dividing cells. Classes include small-molecule tyrosine kinase inhibitors (TKIs), monoclonal antibodies, antibody-drug conjugates (ADCs), and PARP inhibitors. Treatment requires biomarker testing to identify actionable alterations such as EGFR, ALK, HER2, BRAF, BRCA, or NTRK, enabling a precision medicine approach that often achieves superior responses with fewer systemic side effects than conventional chemotherapy. Resistance is managed through sequential therapy and rational drug combinations.
- Biomarker-Driven Treatment Selection
- Next-Generation Targeted Therapies
- Antibody-Drug Conjugates
- Oral Treatment Options
- Manageable Side Effect Profile
- Resistance Management
CLINICAL CANCER INDICATIONS
Key Cancers Treated with Targeted Therapy in China
Precision biomarker-driven kinase inhibitors, next-generation ADCs, and multi-target agents matching individual tumor genomic alterations:
WHY CHOOSE US
Why Choose China Cancer Help for Targeted Therapy
A specialized cross-border continuum providing international patients with direct access to China’s leading targeted oncology pipeline.
China is a global leader in targeted therapy, driven by the uniquely high prevalence of EGFR mutations (40–50% of NSCLC) and other actionable biomarkers in its patient population. Domestic biopharmaceutical companies — Innovent, BeiGene, Hengrui, Chipscreen, and others — have developed multiple world-class targeted drugs, including furmonertinib (third-generation EGFR TKI), zanubrutinib (BTK inhibitor, FDA-approved), and surufatinib, with several reaching global markets through FDA and EMA approvals.
National volume-based procurement and NRDL negotiations have dramatically cut prices: osimertinib, gefitinib, and other once-expensive TKIs are now available at a fraction of Western list prices. The NMPA’s fast-track approval pathways mean novel agents reach Chinese patients rapidly, sometimes before US or European approval. With Grade 3A centers offering NGS molecular diagnostics, MDT molecular tumor boards, and bilingual international patient services, China provides some of the most accessible and advanced targeted oncology care in the world.
CASE EVALUATION PATHWAY
A Structured Pathway from Records to Care
A transparent, four-stage continuum connecting preliminary clinical evaluation to official hospital acceptance, specialized inpatient care, and ongoing continuity.
01. Submit Records Online
02. Pre-Screen & Doctor Match
03. Doctor Consultation
04. Travel to China & Care
PATIENT FAQS
Frequently Asked Questions
Key clinical, financial, and logistical insights for international Molecular Targeted Therapy patients considering care in China.
TARGETED THERAPY PRE-ASSESSMENT
Request a Confidential Case Review for Targeted Therapy
Submit your contact details, confirmed diagnosis, and main question below. You do not need to upload any medical files at this stage. Our clinical coordinator will contact you directly within 24–48 hours to discuss potential targeted oncology therapy pathways in China and assist you in gathering the specific medical records needed for expert hospital review.